Medical Policy

This document addresses surgical treatments for obstructive sleep apnea (OSA), such as uvulopalatopharyngoplasty (UPPP), hyoid myotomy and jaw realignment surgery, laser surgery, radiofrequency ablation, palatal implants, hypoglossal nerve stimulation (HNS) and other procedures. This document does not address tonsillectomy, adenoidectomy or nasal surgery.

Note: For information related to other technologies utilized in the diagnosis and management of sleep-related disorders, please see:

• DME.00042 Electronic Positional Devices for the Treatment of Obstructive Sleep Apnea
• MED.00002 Selected Sleep Testing Services
• CG-MED-79 Diaphragmatic/Phrenic Nerve Stimulation and Diaphragm Pacing Systems
• CG-SURG-30 Tonsillectomy for Children with or without Adenoidectomy
• CG-SURG-36 Adenoidectomy

Note: Please see the following document for the use of nasal surgery to treat snoring and OSA:

• CG-SURG-87 Nasal Surgery for the Treatment of Obstructive Sleep Apnea and Snoring

Medically Necessary:

Uvulopalatopharyngoplasty (UPPP):

Uvulopalatopharyngoplasty (UPPP) is considered medically necessary when all of the following criteria (A-D below) are met:

1. Documented OSA with apnea hypopnea index (AHI) or respiratory disturbance index (RDI) meeting any of the following:
   1. UPPP as sole procedure with AHI (or RDI) greater than 15 events per hour and less than 40 events per hour,
      or
   2. UPPP as sole procedure with AHI (or RDI) between 10-15 events per hour and one or more of the conditions listed below:
      1. Hypertension; or
      2. Cardiac arrhythmias predominately during sleep; or
      3. Pulmonary hypertension; or
      4. Documented ischemic heart disease; or
      5. Impaired cognition or mood disorders; or
      6. History of stroke; or
      7. Excessive daytime sleepiness, as documented by either a score of greater than 10 on the Epworth Sleepiness Scale or inappropriate daytime napping, (for example, during driving, conversation or eating) or sleepiness that interferes with daily activities.
         or
   3. UPPP as part of a planned staged or combined surgery aimed at also relieving retrolingual obstruction, (for example, genioglossal advancement, hyoid myotomy and suspension) with AHI (or RDI) greater than 15 events per hour,
      or
   4. UPPP as part of a planned staged or combined surgery aimed at also relieving retrolingual obstruction, (for example, genioglossal advancement, hyoid myotomy and suspension) with AHI (or RDI) between 10-15 events per hour and one or more of the conditions listed below:
      1. Hypertension; or
      2. Cardiac arrhythmias predominately during sleep; or
      3. Pulmonary hypertension; or
      4. Documented ischemic heart disease; or
      5. Impaired cognition or mood disorders; or
      6. History of stroke; or
      7. Excessive daytime sleepiness, as documented by either a score of greater than 10 on the Epworth Sleepiness Scale or inappropriate daytime napping, (for example, during driving, conversation or eating) or sleepiness that interferes with daily activities.
         and
2. Have failed treatment with CPAP as demonstrated by either of the following (1 or 2):
   1. An AHI greater than 15 when using PAP therapy for greater than 4 hours each night on at least 70% of nights; or
   2. Inability to tolerate CPAP despite adjustments over at least a 1 month period;
      and
3. Fiberoptic endoscopy suggests retro-palatal narrowing is the primary source of airway obstruction if UPPP is the sole procedure or a contributing source of airway obstruction if part of a planned staged or combined surgery aimed at also relieving retrolingual obstruction;
   and
4. The individual is 18 years of age or older, or there is documentation that skeletal growth is complete based on long bone x-ray or serial cephalometrics showing no change in facial bone relationships for at least the last 3 consecutive months.

Soft Tissue Reconstruction:

Hyoid myotomy and suspension, with or without mandibular osteotomy with genioglossus (tongue) advancement, for the treatment of OSA is considered medically necessary when all of the following criteria (A-D below) are met:

1. The treatment of OSA in the individual is medically necessary based on either 1) or 2) below:
   1. AHI or RDI greater than or equal to 15 events per hour;
      or
   2. AHI (or RDI) greater than or equal to 5 events per hour, and less than 15 events per hour with documentation demonstrating any of the following symptoms:
      1. Excessive daytime sleepiness, as documented by either a score of greater than 10 on the Epworth Sleepiness scale or inappropriate daytime napping, (for example, during driving, conversation or eating) or sleepiness that interferes with daily activities; or
      2. Impaired cognition or mood disorders; or
      3. Hypertension; or
      4. Ischemic heart disease or history of stroke; or
      5. Cardiac arrhythmias, or
      6. Pulmonary hypertension.
         and
2. The individual has failed treatment with CPAP as demonstrated by either of the following (1 or 2):
   1. An AHI greater than 15 when using PAP therapy for greater than 4 hours each night on at least 70% of nights; or
   2. Inability to tolerate CPAP despite adjustments over at least a 1 month period;
      and
3. There are significant soft tissue and/or tongue base abnormalities with airway collapse. (Objective evidence of hypopharyngeal obstruction may be documented by either fiberoptic endoscopy or cephalometric radiographs.
   and
4. The individual is 18 years of age or older, or there is documentation that skeletal growth is complete based on long bone x-ray or serial cephalometrics showing no change in facial bone relationships for at least the last 3 consecutive months.

Jaw Realignment Surgery:

Jaw realignment surgery (that is, maxillomandibular advancement) is considered medically necessary when all of the following criteria (A-D below) are met:

1. The treatment of OSA in the individual is medically necessary based on either 1) or 2) below:
   1. AHI or RDI greater than or equal to 15 events per hour;
      or
   2. AHI (or RDI) greater than or equal to 5 events per hour, and less than 15 events per hour with documentation demonstrating any of the following symptoms:
      1. Excessive daytime sleepiness, as documented by either a score of greater than 10 on the Epworth Sleepiness scale or inappropriate daytime napping, (for example, during driving, conversation or eating) or sleepiness that interferes with daily activities; or
      2. Impaired cognition or mood disorders; or
      3. Hypertension; or
      4. Ischemic heart disease or history of stroke; or
      5. Cardiac arrhythmias, or
      6. Pulmonary hypertension.
         and
2. The individual has failed treatment with CPAP as demonstrated by either of the following (1 or 2):
   1. An AHI greater than 15 when using PAP therapy for greater than 4 hours each night on at least 70% of nights; or
   2. Inability to tolerate CPAP despite adjustments over at least a 1 month period;
      and
3. The individual has failed surgical intervention with any of the following:
   1. UPPP; or
   2. Genioglossus advancement and/or hyoid myotomy with suspension; or
   3. Both of these surgical procedures.
      and
4. The individual is 18 years of age or older, or there is documentation that skeletal growth is complete based on long bone x-ray or serial cephalometrics showing no change in facial bone relationships for at least the last 3 consecutive months.

Jaw realignment surgery is also considered medically necessary for individuals with a documented severe jaw/facial bony abnormality that contributes to OSA, including, but not limited to, craniofacial abnormalities, micrognathia, retrognathia or small retro-positioned jaw with associated overbite and small mouth.

Note: Individuals undergoing jaw realignment surgery may also undergo orthodontic therapy. Orthodontic therapy (that is, placement of orthodontic brackets and wires) may not be a covered benefit under all member benefit plans.

Hypoglossal nerve stimulation

Hypoglossal nerve stimulation may be considered medically necessary when all of the following criteria (A-E below) are met:

1. AHI or RDI greater than or equal to 15 events per hour and less than or equal to 65 events per hour; and
2. Central or mixed apneas make up less than 25% of total AHI or RDI score; and
3. Body Mass Index (BMI) of 32 or less; and
4. Absence of complete concentric collapse at the soft palate level during drug-induced sleep endoscopy; and
5. The individual has failed treatment with CPAP as demonstrated by either of the following (1 or 2):
   1. An AHI greater than 15 when using PAP therapy for greater than 4 hours each night on at least 70% of nights; or
   2. Inability to tolerate CPAP despite adjustments over at least a 1 month period.

In addition to the general criteria above, hypoglossal nerve stimulation may be considered medically necessary to treat OSA for individuals with Down Syndrome when all of the following criteria are met:

1. Individual is 10 years of age or older; and
2. AHI or RDI greater than or equal to 10 events per hour and less than or equal to 50 events per hour following adenotonsillectomy; and
3. Central or mixed apneas make up less than 25% of total AHI or RDI score; and
4. The individual’s body mass falls within the following age-based range:
   1. BMI less than or equal to the 95th percentile for individuals under age 18; or
   2. BMI of 32 or less in individuals age 18 or over; and
5. Absence of complete concentric collapse at the soft palate level during drug-induced sleep endoscopy; and
6. Inadequate treatment as evidenced by one or more of the following:
   1. Lack of benefit from positive airway pressure (PAP) treatment (for example, due to nonadherence, discomfort, undesirable side effects, or to persistent symptoms despite compliance), or
   2. Tracheotomy use during sleep.

Not Medically Necessary:

UPPP, soft tissue reconstruction, jaw realignment surgery, or hypoglossal nerve stimulation are considered not medically necessary when the criteria above are not met.

The surgical treatment of snoring without OSA is considered not medically necessary in all cases.

Investigational and Not Medically Necessary:

Other surgical treatments for OSA are considered investigational and not medically necessary.

General Considerations

In 2009, the American Academy of Sleep Medicine (AASM), formerly known as the American Sleep Disorders Association, released the Clinical Guideline for the Evaluation, Management and Long-term Care of Obstructive Sleep Apnea in Adults. This guideline addressed several surgical treatments of OSA, including the following:

• Individuals with severe OSA should have an initial trial of nasal CPAP because greater effectiveness has been shown with this intervention than with the use of oral appliances (OAs).
• Evaluation for primary surgical treatment can be considered in persons with mild OSA who have severe obstructing anatomy that is surgically correctible, (for example, tonsillar hypertrophy obstructing the pharyngeal airway).
• Although the specifics of sleep apnea surgeries are beyond the scope of this guideline, surgical procedures may be considered as a secondary treatment for OSA when the outcome of positive airway pressure (PAP) therapy is inadequate, such as when the individual is intolerant of PAP, or PAP therapy is unable to eliminate OSA.
• Surgery may also be considered as an adjunct therapy when obstructive anatomy or functional deficiencies compromise other therapies or to improve tolerance of other OSA treatments.
• Maxillary and mandibular advancement (MMA) can improve polysomnography (PSG) parameters comparable to CPAP in the majority of individuals.
• Most other sleep apnea surgeries are rarely curative for OSA but may improve clinical outcomes, (e.g., mortality, cardiovascular risk, motor vehicle accidents, function, quality of life (QOL), and symptoms).
• Laser-assisted uvulopalatoplasty (LAUP) is not recommended for the treatment of obstructive sleep apnea (Epstein, 2009).

In 2010, the AASM published practice parameters for Surgical Modifications of the Upper Airway for OSA in Adults (Aurora, 2010), which were based on a systematic review and meta-analysis of the evidence currently available (Caples, 2010). Authors of the systematic review/meta-analysis reported that the bulk of the published literature consisted of case series, with a few controlled trials. The studies were characterized by considerable heterogeneity, including varying approaches to pre-operative evaluation and postoperative follow-up. Using the change in AHI as the primary measure of efficacy, substantial and consistent reductions were observed following MMA, and adverse events were not commonly reported. Outcomes following pharyngeal surgeries were less consistent, and adverse events were more commonly reported.

The following is excerpted from the AASM practice parameters:

• MMA, UPPP as a sole procedure or multi-level, or stepwise surgery following failed UPPP as a sole treatment - all received a recommendation of “Option” (uncertain clinical use), due to the lack of rigorous data evaluating surgical modifications of the upper airway;
• Radiofrequency Ablation (RFA) also received a recommendation of “Option” for individuals with mild to moderate OSA who cannot tolerate or who are unwilling to adhere to CPAP, or in whom oral appliances have been found ineffective or undesirable;
• Palatal implants received a recommendation of “Option” for those with mild OSA who failed medical therapy;
• LAUP was not recommended as a routine treatment for OSA (“Standard”).
• A recommendation of “Standard” was given for the determination of the presence and severity of OSA before initiating surgical therapy, discussion of success rates, complications, and alternative treatments with the individual, and a postoperative follow-up evaluation, which includes a clinical evaluation and an objective measure of the presence and severity of sleep-disordered breathing and oxygen saturation, although it was noted that little guidance was available in the medical literature to recommend any particular monitoring strategy nor optimal intervals and duration of follow-up (Aurora, 2010).

UPPP

There is widespread agreement in the published studies of UPPP, as to the definition of "success" of the procedure. This is defined as a reduction in pre-operative AHI/RDI or Apnea index (AI) by at least 50% with a post UPPP AHI/RDI of less than 20; or a post UPPP AI less than 10. Using these definitions, a person whose pre-operative AHI/RDI/AI is less than 10 is already (by definition) "cured" of their OSA and is, therefore, not an appropriate candidate for UPPP. Furthermore, there is no published literature that supports the value of UPPP for this group.

Studies evaluating UPPP or modified UPPP as a sole treatment of OSA have reported decreased AHI from baseline maintained in the long-term, although several studies have showed a declining therapeutic effect over time (Friberg, 2020; Neruntarat, 2011; Sundman, 2021). In a meta-analysis, He and colleagues (2019) analyzed the long-term outcomes (at least 34 months) of UPPP as a sole treatment of OSA. A total of 11 studies were included. The mean AHI at baseline was 39.9 ± 18.3 in 6 studies and 43.2 ± 17.7 in 4 studies. Compared with the short-term studies, long-term studies showed a mean AHI increase of 12.3. Despite a decreasing curative effect, the mean AHI remained improved over baseline.

There is recognition in the literature that UPPP, when performed as the sole procedure, is less likely to be a success when severe OSA is present preoperatively. The AASM defines "severe" as an AHI/RDI greater than 30. There is evidence that UPPP, when performed for individuals with an AHI/RDI greater than 40, is unsuccessful in the vast majority of cases (Friedman, 2005; Millman, 2000). This may, in part, be related to the presence of unrecognized coexistent hypopharyngeal obstruction in persons with severe OSA that could not be expected to be adequately relieved by UPPP alone, which addresses only velopharyngeal (retropalatal) obstruction. Multilevel upper airway collapse, which is often present in those with OSA, may be only partially relieved by a single procedure (Yang, 2020).

There are a limited number of studies assessing the efficacy of multilevel surgery. Yang and associates (2020) compared the efficacy of hyoid myotomy and suspension with UPPP to CPAP therapy in individuals with moderate to severe OSA. In the case series study (n=15), individuals who failed or refused CPAP therapy underwent surgery. The results of each type of therapy were compared in the same individuals. While there were improvements in OSA severity and oxygen desaturation following both treatments, the individuals showed improved sleep stage, and blood pressure control during CPAP therapy.

The decreased efficacy over time is thought to be related to multiple factors, such as the tendency to gain weight as well as increased laxity in the tissue with age. Given the invasive nature of UPPP and the decreased efficacy over time, it is reasonable to limit use of this treatment to those who have failed non-invasive treatment with positive airway pressure therapy.

Soft Tissue Reconstruction

Hyoid myotomy and suspension, and mandibular osteotomy with genioglossus advancement have been demonstrated in multiple case series studies to provide significant relief of symptoms for individuals suffering from OSA where hypopharyngeal (retrolingual) obstruction during sleep is a significant factor (Song, 2016). These soft tissue reconstructive procedures have been shown to successfully alter the anatomy of persons with OSA sufficiently to prevent upper airway collapse. Not all individuals are appropriate for this procedure. Careful evaluation of the upper airway anatomy should take place prior to consideration of this procedure. As with UPPP, hyoid myotomy and suspension, and mandibular osteotomy with genioglossus advancement should not be used as first line treatments, and trials of conservative therapies, such as CPAP, should be attempted first. Hyoid myotomy and suspension, and mandibular osteotomy with genioglossus advancement may be performed, along with UPPP, in selected individuals where both velopharyngeal and hypopharyngeal obstruction during sleep are thought to occur.

A retrospective case series evaluating the surgical outcomes of individuals whose OSA was treated by UPPP and hyoid suspension was published in 2023 (van Tassel). A total of 39 individuals with moderate to severe OSA, obesity, and multiple levels of airway collapse and CPAP therapy failure or intolerance underwent staged or concurrent surgery. A polysomnogram was performed 3 to 9 months following surgery. At follow-up, the median AHI was reduced from 42.0 to 10.8 and the mean AHI declined significantly by 69.2% (49.9 ± 25.6 to 15.4 ± 14.9). Surgical success, defined as a final AHI of 20 or lower or a 50% of greater decline in AHI, was achieved in 76.9% (30/39). Only short-term outcomes were reported in this study.

Jaw Realignment Surgery

The use of jaw realignment surgery in persons with OSA who are unresponsive to other therapies has been demonstrated to be an effective treatment. While the results of this procedure have been shown to significantly improve the symptoms of OSA, jaw realignment surgery involves extensive jaw reconstruction. Several articles in the peer-reviewed literature have proposed a stepwise approach to OSA therapy that requires the use of other conservative and surgical interventions, mainly CPAP and UPPP, prior to consideration of jaw realignment surgery.

A meta-analysis by Zaghi and colleagues (2016) evaluated the efficacy of maxillomandibular advancement as a treatment of OSA. A total of 45 studies with individual data from 518 participants were included. The primary outcomes were the changes in AHI and RDI following surgery. Following surgery, 98.8% (512/518) reported an improvement in AHI and RDI. Mean postoperative changes in AHI and RDI were -47.8 (25.0) and -44.4 (33.0), respectively. The majority of individuals had a history of prior surgery for OSA (197 of 268 [73.5%]). The authors noted, “patients with a high residual RDI and AHI after failure of other surgical procedures for sleep apnea are highly likely to benefit from MMA.”

This conservative approach is appropriate in all but the most extenuating circumstances involving severe maxillofacial malformations related to OSA. Studies have reported success rates of up to 100%, although most studies report a surgical success rate of approximately 80% and OSA cure rates of 30-40% (Buller, 2020; Romano, 2020). The literature on this procedure indicates that success varies with the experience of the surgeon and the facility, and care should be taken in their selection.

Radiofrequency Volumetric Tissue Reduction (RFVTR) or Laser-Assisted Uvulopalatoplasty (LAUP)

There is inadequate evidence in the published medical literature demonstrating the efficacy of radiofrequency (RF) ablation techniques for the treatment of OSA. One particular technique, RFVTR which focuses on the base of the tongue and soft palate and includes two procedures marketed as Somnoplasty and Coblation, has been described in the medical literature. In a multi-institutional study of 56 subjects with OSA treated with radiofrequency tongue base reduction, the mean pre-operative AHI index of 40.5 decreased only to 32.8 after treatment (Woodson 2001). A randomized controlled trial (RCT), involving 90 subjects with mild to moderate OSA, evaluated RFVTR of both tongue and palate in 30 individuals with comparisons to those receiving CPAP or sham radiofrequency treatment. Results showed that there was no significant reduction in either AHI or nocturnal oxygen desaturation in the RFVTR-treated group compared with the CPAP or sham groups (Woodson 2003). A systematic review and meta-analysis of 20 studies was done to evaluate the efficacy of temperature-controlled radiofrequency tissue ablation (TCRFTA) in treating OSA. TCRFTA was categorized based on location: base of tongue, soft palate and multilevel. Analysis showed significant reductions in RDI, Epworth Sleep Scale (ESS), lowest oxygen saturation (LSAT) and snoring for procedures performed at the base of the tongue. TCRFTA at the soft palate showed limited efficacy, although there was a paucity of studies in this area. Multilevel TCFFTA did show a significant reduction in RDI, in the short term. Analysis of AHI was not completed as this outcome was not consistently reported within the studies. The authors reported that the studies were generally of low quality and there was significant heterogeneity which did not allow strong conclusions (Baba, 2015). Studies with longer-term outcomes would be useful in evaluating the benefits of this procedure.

LAUP has primarily been researched as a treatment of snoring without associated clinically significant OSA. There are concerns that OSA may worsen following the LAUP procedure, or OSA may develop if LAUP is used to treat snoring (Camacho, 2017; Epstein, 2009; Franklin, 2009; Göktas, 2014). Camacho and associates (2017) performed a meta-analysis on the use of LAUP as a stand-alone treatment for OSA and concluded:

Statement of Significance

There are three important points. First, laser-assisted uvulopalatoplasty (LAUP) can potentially worsen obstructive sleep apnea (OSA; 44% of patients with individual data). Second, primary snoring patients who no longer snore after LAUP should be tested for OSA post-operatively if they develop signs and symptoms of OSA. Third, given that reflexogenic dilation of the pharyngeal airway is at least partially mediated by pharyngeal mucosa afferent nerve fibers, it is possible that by destroying the surface of the soft palate with a laser, that there may be blunting of the reflexogenic dilation of the pharyngeal airway. Therefore, LAUP should be performed with caution or not performed at all. Proper patient counseling is essential.

Franklin (2009) conducted a systematic review to evaluate the efficacy and adverse effects of surgery for snoring and OSA. The review included four RCTs of surgery versus either sham surgery or conservative treatment in adults, and described outcome measures for daytime sleepiness, QOL, AHI, and snoring. Results of this review found that there was no significant effect on daytime sleepiness and QOL following LAUP or RFVTR. The authors concluded that these studies did not provide evidence of therapeutic effect from LAUP or RFVTR on daytime sleepiness, apnea reduction, QOL, or snoring.

Cautery-assisted palatal stiffening operation (CAPSO)

Llewellyn and associates (2018) performed a meta-analysis to evaluate the clinical outcomes of CAPSO used to treat OSA. The meta-analysis included individuals who underwent CAPSO as the sole treatment (n=80), CAPSO with tonsillectomy (n=92) and CAPSO with expansion pharyngoplasty (n=78). Each group saw a decrease in mean AHI from baseline to post procedure; CAPSO alone showed a 41.1% decrease, CAPSO with tonsillectomy reported a 61.7% decrease, and CAPSO with expansion pharyngoplasty recorded a 52.1% decrease. While the study noted post-operative decreases in AHI, there was limited data regarding the length of time the participants were followed. Additional limitations of the meta-analysis include a limited number of studies and participants, the presence of significant heterogeneity, and the lack of randomized studies available.

CAPSO has been suggested as a treatment of snoring or mild OSA. Evidence from earlier studies were limited by a focus on snoring rather than OSA, small size and poor outcomes (Mair, 2000; Wassmuth, 2000). The limited evidence available does not support that CAPSO provides equivalent clinical benefit when compared to the established alternatives.

ENCORE Tongue Suspension System

Additional treatment methods proposed for OSA utilize the ENCORE Tongue Suspension System (Siesta Medical, Inc., Los Gatos, CA) or the AIRvance (formerly the Repose) Bone-anchored Suspension System (Medtronic, Inc., Minneapolis, MN), and also injection snoreplasty. To date, these treatments have not been evaluated in large, controlled trials with long-term outcomes data. At this time, there is insufficient evidence to make any recommendation about the appropriate clinical use of either tongue base suspension systems or injection snoreplasty.

Pillar palatal implant system

The literature has been limited regarding the safety and efficacy of the Pillar palatal implant system for treating OSA. Friedman reported a single institution RCT involving 62 subjects with mild to moderate OSA who were selected based on "Friedman tongue position," soft palate size, and body mass index (BMI) less than 32. Only 29 participants actually received the palatal implant and follow-up analysis. A total of 26 participants underwent a "sham" procedure and analysis as the placebo group. Follow-up was performed at 3 months, and success was defined as an AHI reduction of at least 50% and a post-procedure AHI less than 20. On this basis, 13/29 subjects receiving the implants were a success (44.8%), compared to 0 in the placebo group. However, 4 of the 13 "successes" already had a pre-procedure AHI of less than 20, as did 9 of the 26 in the placebo group. In the implant group, the mean AHI fell from 23.8 to 15.9, this latter number still representing moderate OSA, (as defined by the AASM). In addition, the mean Epworth Sleepiness Scale score fell from 12.7 to 10.2, the latter continuing to represent excessive daytime sleepiness (greater than 10). No individual data were reported, and it is unknown if OSA was completely relieved (AHI less than 5) in any of the trial participants. Mean minimum O₂ saturation rose from 88.3% to 89.7% (significance unclear) with QOL responses following treatment that were measured using an SF 36 rather than a more specific sleep-related QOL measurement tool. Acknowledged limitations of the study by the authors were the short follow-up (which precludes conclusions regarding the durability of the implant procedure) and the potential challenge in generalizing results arising from a limited study population of non-obese, mild to moderate OSA subjects with specific oral physical characteristics where half of the participants evaluated did not qualify for the study (Friedman, 2008).

The available studies to date do not provide convincing evidence of the long-term efficacy of palatal implants in persons with OSA. The studies are restricted by small size, missing data, limited follow-up and large numbers of drop-outs within the study (Friedman, 2008; Walker, 2007). Walker (2007) reported a substantial number of individuals who experienced an increase in mean AHI at 90 days post-procedure compared to pre-procedure. Larger randomized controlled trials with longer follow-up and more complete participant data post-procedure are required to establish the procedure's efficacy for OSA.

Transpalatal advancement pharyngoplasty (TAP or TPAP)

Another technique that has been proposed as a surgical alternative for the treatment of OSA is TAP or TPAP. This surgical procedure alters the retro-palatal airway by advancing the palate forward without requiring excision of the soft palate. This procedure pulls the palate forward and superiorly. Conceptually, similarities exist to maxillary advancement without the associated alterations in dentition. The TAP procedure has been purported for use alone or in combination with other soft tissue surgeries for individuals with narrowing in the retro-palatal airway, especially narrowing proximal to the point of palatal excision using traditional UPPP techniques. A transpalatal approach and advancement has also been proposed for individuals with obstructions in the nasopharynx, such as enlarged adenoids, that cannot be accessed through traditional techniques. In a meta-analysis and systematic review, Volner and colleagues (2017) evaluated the effect of TPAP on the AHI and lowest oxygen saturation (LSAT). Studies were included when TPAP was used to treat OSA and no other surgeries addressing other levels of obstruction were performed at the same time. A total of 5 studies dating from 1993 to 2014 with 199 participants were included. The relative reduction in AHI was 64.8% (mean ± standard deviation of 54.6 ± 23.0 [95 % confidence interval (CI), 51.4, 57.8] to 19.2 ± 16.8 [95 % CI, 16.9, 21.5] events/hour). The mean LSAT difference improved from 81.9 ± 8.1 to 85.4 ± 6.9 with a mean difference of 3.55. However, only 70 participants had data available regarding the LSAT and when one study was removed from the analysis, the mean difference was 0.62. There were multiple limitations associated with analysis including the quality of the studies, the lack of comparison with other surgical procedures and the potential for author bias (the individual who developed the procedure authored 3 of the studies). A retrospective review not included in the analysis described 30 subjects who underwent a TAP procedure; 20 of these study subjects also had various tongue-base procedures performed at the same time as TAP (Woodson, 2005). Only 10 had TAP alone. The results of postoperative AHI in these 30 subjects were better than a comparable group of 44 subjects undergoing UPPP, 26 of whom had UPPP as the sole procedure. Also, for the subjects in each group who did not have additional tongue base surgery, the AHI improved significantly more in the TAP treated group (n=10) than the UPPP treated group (n=26). Larger studies are needed to establish the safety/efficacy of the TAP procedure, together with prospective comparisons with established palate-based surgical techniques.

Hypoglossal nerve stimulation (HNS)

The Inspire II Upper Airway Stimulation System (UAS) (Inspire Medical Systems, Maple Grove, MN) was approved by the FDA in April 2014. The Inspire UAS is approved for use in a subset of adults with moderate to severe OSA with an AHI between 15-65. In addition, evaluation must show that individuals do not have a complete concentric collapse at the soft palate level. Inspire UAS is considered a second level treatment and individuals must have failed or cannot tolerate PAP therapy as noted below:

PAP failure is defined as an inability to eliminate OSA (AHI of greater than 20 despite PAP usage), and PAP intolerance is defined as:
(1) Inability to use PAP (greater than 5 nights per week of usage; usage defined as greater than 4 hours of use per night), or
(2) Unwillingness to use PAP (for example, a patient returns the PAP system after attempting to use it).

The label warned that individuals with a BMI of greater than 32 were not studied in the pivotal trial. BMIs greater than 32 may be associated with decreased treatment success and treatment with HNS is not recommended in this population. Other contraindications include:

• Central + mixed apneas > 25% of the total apnea–hypopnea index (AHI)
• Any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate
• Any condition or procedure that has compromised neurological control of the upper airway
• Individuals who are unable or do not have the necessary assistance to operate the sleep remote
• Individuals who are pregnant or plan to become pregnant
• Patients who will require magnetic resonance imaging (MRI)
• Individuals with an implantable device that may be susceptible to unintended interaction with the Inspire system. Consult the device manufacturer to assess the possibility of interaction.

Previously the need for an MRI was a contraindication. The need for an MRI is now considered a conditional indication; MRIs can be performed under certain conditions if the appropriate precautions are followed.

In a prospective, multicenter single-group design, Strollo and associates (2014) evaluated the safety and effectiveness of upper airway stimulation using the Inspire Upper Airway Stimulation system (Stimulation Treatment for Apnea Reduction (STAR)). A total of 126 individuals with moderate to severe OSA, BMI of 32 or lower and low adherence to CPAP were included. Individuals were excluded if there was complete concentric collapse of the retropalatal airway observed during drug-induced sleep endoscopy. Primary outcome measures included AHI and oxygen desaturation index (ODI). At 12 months of follow-up, 60% of participants achieved at least a 50% decrease in AHI. The median AHI decreased 68%, from 29.3 to 9.0 events/hour (mean, 32.0-15.3). The first consecutive 46 participants who were treatment responsive were subsequently randomized to either continued therapy or withdrawal from therapy. After 7 days, AHI of the continued treatment group remained stable from a mean of 7.2 to 8.9 events per hour, while the mean AHI in the withdrawal group increased from 7.6 to 25.8. Two participants experienced serious adverse events associated with the device.

Researchers continued to follow the STAR participants through 5 years post-procedure. At 18 months, the AHI maintained the decrease from baseline, with a median AHI of 9.7 at 18 months. There were no new safety concerns raised (Strollo, 2015). At 36 months, 92% (116/126) of participants completed a follow-up evaluation and 78% (98/126) underwent a follow-up polysomnogram. The median AHI was 6.2. The self-reported daily used was reported at 81% (Woodson, 2016). In 2018, Woodson and associates reported on the 5-year outcomes of the STAR trial. With 78% (97/126) completing a follow-up evaluation, the mean AHI improvement was maintained (12.4 ± 16.3). After 5 years, 8 individuals (6%) had serious device-related AEs which required surgery to replace or revise the device.

Certal and colleagues published a systematic review and meta-analysis on HNS (2015). A total of six studies (five prospective case series and one case report) with 200 participants were included. A pooled, fixed results analysis demonstrated significant improvements in AHI at the 3-, 6- and 12-month timepoints (43.90 ± 17.61/hour (hr) to 20.03 ± 14.15/hr; 43.73 ± 16.55/hr to 18.91 ± 16.47/hr; and 35.45 ± 13.26/hr to 17.55 ± 16.94/hr respectively). In addition, there were statistically significant reductions in ODI and ESS. There were no reported safety concerns, and none of the studies reported any serious adverse events.

The Adherence and Outcome of Upper Airway Stimulation for OSA International Registry (ADHERE), an industry sponsored cohort of individuals who received the Inspire device from multiple sites in the United States and Europe, was designed as a follow-up to the STAR trial (Boon, 2018). The registry included those who met the following criteria: moderate to severe OSA, intolerance or inadequate adherence to CPAP, favorable anatomic criteria (a lack of complete concentric collapse of the retropalatal airway observed during drug-induced sleep endoscopy), device implantation and a willingness to return for routine clinic visits as required. Data was collected retrospectively in those participants who underwent device implantation prior to the creation of the registry and chose to participate in the registry. Registry participation was purely observational; there were no required study specific procedures or treatment plans (Boon, 2018). The ADHERE registry anticipates enrolling a total of 2500 participants. A total of 1017 participants had been enrolled between October 2016 and February 2019 (Thaler, 2020). The registry is comprised of a collection of retrospective and prospective outcome measures, with the first set of data published in 2018 (Boon). Since that time, several studies have been published using the data from the ADHERE registry.

Boon and associates (2018) evaluated the objective and subjective treatment outcomes, adverse events, and patient and physician satisfaction levels in the first 301 participants enrolled in the ADHERE registry. The mean AHI decreased from 35.6 ± 15.3 to 10.2 ± 12.9. Withrow and associates (2019) used data from the ADHERE registry to evaluate the impact of age on safety, efficacy, and usage of upper airway stimulation. The study included the data from 600 individuals, which was 20% of the population which had been treated with HNS (600/3000) at the time. The clinical outcomes of participants younger than 65 years old were compared to the clinical outcomes of those aged 65 and older. Both groups showed a significantly lower AHI at 12 months post-procedure, the older group showed a greater reduction. Heiser and colleagues (2018) reviewed the data of 508 participants to identify the predictors of success. The authors concluded that increasing age and reduced BMI were predictors of treatment response. In 2020, Thaler and colleagues reported on the results of 640 individuals who are enrolled in the ADHERE registry and have completed their 6-month follow-up post implantation. An additional 382 individuals have completed a 12-month follow-up. The median AHI was reduced from 32.8 at baseline to 9.5 at 12 months follow-up.

In the first comparative study between PAP and HNS, Walia and associates (2020) compared improvements in blood pressure, daytime sleepiness (ESS) and therapy usage. The clinical outcomes of a portion of ADHERE (HNS) participants were retrospectively compared against consecutive individuals treated with PAP therapy at a single institution. Following propensity score matching, there were 201 individuals in each group. The average follow-up was 108 days in the PAP group and 134 days in the HNS group. The PAP therapy group showed a greater improvement in blood pressure readings, with the improvement in diastolic readings reaching statistical significance. Both groups showed an improvement in ESS scores. The HNS group reported higher nightly usage rates.

Costantino and colleagues (2020) performed a systematic review and meta-analysis evaluating the clinical outcomes associated with the use of HNS in individuals with moderate to severe OSA and CPAP non-adherence. A total of 12 prospective studies were included in the systematic review and 9 prospective studies were included in the meta-analysis. All included studies were generally of high quality. When compared to baseline (pre-implantation), the 6-month AHI mean difference for the Inspire device was -17.74 (95% CI: -24.73 to -10.14, Z score = 4.97, p<0.001). That improvement remained at 12 months (-17.50, 95% CI: -20.01 to -14.98, Z score = 13.64, p<0.001). The ODI and ESS also showed significantly improved scores at 6 and 12 months. The 3 studies which evaluated long-terms outcomes, ranging from 18 to 60 months, were STAR trial follow-ups. The AHI mean was decreased at 18 months and remained decreased through the 36- and 60-month follow-up (32.0 ± 11.8/h to 14.1 ± 14.4/h [n=123], 30.4 ± 10.4/h to 11.5 ± 13.9/h [n=98], and 30.4 ± 9.4/h to 12.4 ± 16.3/h [n=71], respectively). After 5 years, 6% of individuals were reported to have device-related complications requiring surgical repositioning or replacement. Self-reported device use remained steady at 1, 3 and 5 years (86%, 81% and 80%, respectively). The authors note the results are promising, given that this population, which has failed other therapies, may be more difficult to treat.

In June 2023, the FDA expanded indications for the Inspire device to include individuals with an AHI of up to and including 100 and a BMI up to and including 40. The AHI expansion was based on an analysis of 57/3988 individuals enrolled in the ADHERE Registry with an AHI greater than 65 and less than or equal to 100. The BMI expansion was based on an analysis of 297/3988 individuals enrolled in the ADHERE Registry with a BMI of greater than 32. Continued approval of the PMA requires that the manufacturer complete a post-approval study to support the expanded indications. The Inspire UAS High AHI High BMI New Enrollment study will be a multi-center, 2-arm prospective study which will include individuals with AHIs between 65 and 100 in one arm and individuals with BMIs between 32 and 40 in the other arm. Participants will be followed for a minimum of 5 years.

Suurna and colleagues (2021) used the data from the ADHERE registry to analyze clinical outcomes based upon the initial BMI of participants with complete baseline and final assessment data. UAS therapy adherence and efficacy outcomes in participants with a BMI of less than 32 (BMI₃₂, n=438) were compared against participants with a BMI between 32 and 35 (BMI₃₅, n=97). The final change in AHI in the BMI₃₅ group was noninferior to the BMI₃₂ group_. Individuals in the BMI₃₅ had a significantly lower likelihood of achieving an AHI of less than 20 events/hour. The study authors theorized that higher BMI is associated with increased airway closure pressure which might impact efficacy of treatment at comfortable UAS levels. Individuals in the BMI₃₅ also reported lower therapy usage.

Bosschieter and colleagues (2022) utilized the ADHERE registry data to compare the clinical outcomes of UAS therapy based upon OSA severity at baseline, as measured by AHI. The authors created 5 groups; group 5 consisted of individuals with an AHI of greater than 65 (n=77). At 12 months post-implantation, there was a significant improvement in all groups with an AHI of greater than 15. While group 5 reported the largest AHI reduction, there was 12-month AHI data on only 33 participants.

Analysis based upon the ADHERE registry is limited by potential bias as the registry does not record individuals who refuse participation. Studies outside the ADHERE registry data evaluating UAS therapy in individuals with a BMI of greater than 32 are limited to retrospective studies (Boroosan, 2022; Huntley, 2018). The conclusions of these studies are mixed. Boroosan and colleagues (2022) attempted to identify prognostic factors in a cohort of 39 individuals and concluded that BMI of greater than 32 is a negative predictor. In a case control retrospective review, Huntley and associates (2018) did not identify a difference between the BMI cohorts. Further evaluation of individuals outside the original FDA approved indications is needed before the safety and efficacy of UAS therapy can be established.

HNS in the Down syndrome (DS) Population

OSA is a common diagnosis for individuals with DS affecting 30-76% of children and 65-100% of adults. More than half of these cases categorized as severe OSA (Giménez, 2021). DS is associated with phenotypic and physiologic factors that predispose affected individuals to OSA. These include small oropharynx, mandibular and mid-facial hypoplasia, adentonsillar hyperplasia (Giménez, 2021). In addition to anatomical abnormalities, individuals with DS exhibit hypotonia that can exacerbate an obstruction (Li, 2019). In the pediatric population, adenotonsillectomy is the first-line treatment, but is not as effective for children with DS. Adenotonsillectomy resolves OSA in approximately 80% of children without DS. OSA severity is reduced, but not resolved in 50-75% of children with DS treated with adenotonsillectomy. Airway support may be needed following adenotonsillectomy, however approximately 50% of individuals with DS are noncompliant with airway support therapy due to “a high frequency of coincident sensory integration disorders” (Stenerson, 2021). Giménez and associates (2021) summarized the effects of consequences of OSA:

OSA is a systemic disorder that affects cardiovascular and metabolic systems, as well as cognitive functioning. Due to the cognitive and medical comorbidities associated with DS, the consequences of OSA may have a greater impact in this population.

In a pilot study, a total of 42 children and adolescents with DS and moderate to severe OSA refractory to adenotonsillectomy and PAP therapy were implanted with an HNS device. Stenerson (2021) reported on the extended follow-up (44-58 months) in the first 4 participants. Participants had an AHI between 10 and 50 events/hour with a central apnea contribution of < 25%, previous adenotonsillectomy, BMI < the 95th percentile for their age, and either an inability to tolerate PAP therapy or dependence on tracheotomy during sleep. AHIs were reported as 21.0 to 30.7 at baseline and 2.9 to 11.0 (2.9, 3.8, 5.0 & 11.0) one-year post-implantation. At the most recent reported evaluation, the AHI remained within ± 3.8 of the one-year results, with 2 participants exhibiting an AHI of 0 and 2 individuals reported as moderate OSA (5.2, 9.5). The QOL scores improved in all 4 participants in the first year postoperative period, but at the most recent evaluation, one participant reported worsening QOL. The reason for the worsening QOL was not known, but it was theorized that questionnaires might have been filled out by different caregivers resulting in inconsistent results. The authors summarized that HNS “offers potentially long-lasting therapeutic benefit to patients with DS whose OSA persists into adulthood and is insufficiently managed by standard treatments.”

Yu and associates reported on the 12-month outcomes of 42 adolescents with DS who were treated with HNS therapy. Eligible participates were between the ages of 10 and 22 years old with persistent severe OSA (AHI of at least 10) following adenotonsillectomy and 25% or less of the events were due to central apnea. Individuals had a BMI under the 95^th percentile for their age and either had the inability to tolerate PAP therapy or were dependent upon tracheostomy during sleep. Therapy response, defined as a 50% decrease in AHI from baseline, was set as the primary outcome. At 12 months, the mean decrease in AHI of 12.9 (95% CI, –17.0 to –8.7). A total of 65.9% of participants (27/41) were classified as therapy responders. Over 70% of participants (30/41) had an AHI of less than 10 at 12 months. only 34.1% (14/41). An AHI of less than 5 was observed in 34.1% (14/41) at 12 months. Reoperation was required in 2 individuals and 4 individuals had device or surgery related readmissions. Worsening of central apnea following device activation was reported in one participant. The authors concluded that HNS in this cohort has “an acceptable adverse event profile with high rates of therapy response and quality of life improvement.”

The reported AHI improvements demonstrated in the pediatric population was seen for three adults with DS and severe OSA who were intolerant of CPAP (Li, 2019). The presence of complete circumferential velopharyngeal collapse was ruled out by drug-induced sleep endoscopy for all 3 prior to HNS implantation. At the first and second postoperative evaluation the titrated AHIs were 0, 6.8 and 0.6 and 12 and 0, respectively. One participant did not undergo a second postoperative evaluation with titration. The procedure was well tolerated and there were no permanent complications although one individual exhibited transient marginal mandibular nerve weakness.

Although the benefits of HNS therapy to treat individuals with DS and OSA have yet to be demonstrated in RCTs, evidence from a growing body of case series studies is compelling and has resulted in the adoption of this modality to manage individuals with DS.

Failure of CPAP Therapy

CPAP is considered the standard of care for the treatment of moderate to severe OSA. PAP therapy provides pneumatic splinting of the upper airway in order to allow for passive distention (Kushida, 2006). PAP therapy is a noninvasive and effective treatment with minor, reversible side effects. The effectiveness of PAP therapy is limited by adherence to treatment. The Centers for Medicare and Medicaid Services (CMS) defines PAP adherence as “4 or more hours of PAP usage per night for 70% of night in a 30-day period” (Naik, 2019). The use of PAP therapy to treat OSA in individuals with an AHI of 15 or greater is ‘plausible and clinically important” and is based on “reasonably strong epidemiologic evidence that this condition increases the risk of hypertension and cardiovascular morbidity” (CMS, 2001). The use of PAP therapy for at least 4 hours a night has become an established standard component of PAP therapy adherence and has been shown to have some validity as a measure of clinical significance (Sangal, 2020; Weaver, 2008; Wozniak, 2014).

Individuals cite multiple reasons for lack of adherence to PAP therapy including dry mouth, congestion, runny nose or nose bleeds, headaches, bloating, air leaks around the mask and difficulty breathing against airway pressure. Modifications to PAP therapy, trial of other masks, humidification and pressure modification devices may be an option for some individuals (Kennedy, 2019). Other individuals cite conditions such as anxiety or claustrophobia as barriers to PAP therapy. Desensitization programs or the use of less restrictive interface devices may improve adherence in some individuals (Khot, 2022).

Description of Sleep Apnea

OSA syndrome affects over 39 million people in the United States (US). Many of these people have never had a proper diagnosis. OSA is characterized by an interruption of breathing during sleep, due to airway obstruction or collapse. The obstruction may occur at one or at multiple levels such as retropalatal, retrolingual, or nasal cavity. OSA is often linked to obesity and decreased muscle tone due to aging. When the airway becomes blocked, a drop in blood oxygen content can occur which is detected by the brain, causing the individual to wake just enough to tighten the airway muscles and allow breathing to then resume. This may occur several hundred times in one night. OSA can cause many symptoms, such as depression, irritability, sexual dysfunction, learning and memory difficulties, and falling asleep while at work or driving. OSA is recognized as a contributor or primary mediators in several cardiovascular conditions, including atrial fibrillation, stroke, myocardial infarction and sudden cardiac death. Continuous positive airway pressure (CPAP) is considered the gold standard treatment for OSA and an estimated 33 million US adults use a CPAP machine. However, compliance is an issue with an estimated 40-70% of individuals using CPAP less than a therapeutic amount of time (Soose, 2016). There is also a subset of individuals who do not respond adequately to CPAP therapy. Surgical treatment is considered a second-line therapy following failure of PAP trial in most cases. Surgical treatment requires that a thorough preoperative evaluation be done to locate the precise area of obstruction as obstruction can occur at the retropalatal or the retrolingual area or in both areas (Aurora, 2010).

Description of OSA Treatments

UPPP is a surgical procedure involving the removal of excessive tissue in the retropharyngeal area, including tonsils and uvula, to widen the area to increase airflow. Since its inception, a number of modifications have been developed including lateral pharyngoplasty, uvulopalatal flap, Z-palatopharyngoplasty, palatal advancement pharyngoplasty, expansion sphincter pharyngoplasty, relocation pharyngoplasty and zed-plasty. Complications of this surgery may include swelling, pain, infection, bleeding, reflux of secretions into the nose, and a nasal quality to the voice. This procedure typically requires an inpatient stay and is used for the treatment of severe OSA. This procedure can be used alone or when there is multilevel obstruction, as part of a staged procedure.

Hyoid myotomy is a surgical procedure that involves movement of the hyoid bone in the neck. The hyoid bone is a c-shaped bone located above the Adam’s apple, to which the base of the tongue and other soft tissues of the throat are anchored. Hyoid myotomy involves the surgical detachment of these soft tissues from the hyoid bone and then reattachment in a manner that places increased tension on the tissues. This increased tension is intended to decrease soft tissue collapse of the upper airway that is characteristic of sleep apnea. The Airlift^™ system (Siesta Medical; Los Gatos, CA) is a system of implants and instruments used to permanently lift and suspend the hyoid bone, allowing for expansion of the airway during sleep.

Genioglossus advancement is a surgical procedure that involves alteration of the anchor point for the genioglossus muscle of the tongue. This point is located on the inside of the lower jaw. During this procedure, the area of bone surrounding the anchor point is separated from the rest of the jawbone and pulled outward, drawing the tongue away from the back of the throat. This serves to prevent the base of the tongue from blocking the upper airway during sleep.

Jaw realignment surgery is an extensive procedure, in which the upper and lower jaws are advanced several millimeters to improve airflow through the back of the throat. Maxillomandibular advancement (MMA) involves bilateral sagittal split advancement of the mandible and a concurrent Le Fort I advancement of the maxilla. Several surgeries may be required. Persons undergoing jaw realignment surgery typically also undergo orthodontic therapy to correct changes in tooth alignment, associated with the surgery. Change in facial appearance is common in this type of surgery. Other side effects of the procedure include swelling, pain, dental mal-alignment requiring correction, and bleeding.

Many other surgical methods have been proposed for the treatment of OSA, which use various methods of removing or ablating excess tissue from the upper airway, predominantly the soft palate and in some cases the base of the tongue. Of these proposed methods, radiofrequency ablation techniques use high frequency radio waves to destroy tissue of the soft palate, nasal turbinates and/or base of the tongue to decrease excess tissues in the back of the throat. Radiofrequency ablative techniques include RFVTR, Coblation and Somnoplasty. Persons undergoing these procedures frequently require multiple treatments for adequate results. Another category of treatment that aims to remove excess tissue from the upper airway uses heat from either a laser or an electrocautery device to destroy tissue of the soft palate. The two approaches currently available that use this method are LAUP and CAPSO. CAPSO involves denuding the anterior aspect of the soft palate with a blended cautery followed by cauterization of that tissue to further stiffen the palate. CAPSO has been suggested as a less invasive and painful technique compared to other surgical procedures of the palate (Llewellyn, 2018).

Another surgical method proposed for the treatment of OSA is the AIRvance (formerly the Repose) system. This system involves the insertion of a bone screw into the inside of the lower jaw. A cable is then threaded through the base of the tongue and anchored to the bone screw. This system is used to prevent the base of the tongue from falling into the airway, which can be a cause of some OSA symptoms. Similar to the AIRvance System, the ENCORE Tongue Suspension System utilizes a suture loop which is created in the posterior section of the tongue base and is then tensioned and anchored with a bone screw placed midline on the infero-posterior surface of the mandible. The ENCORE System was cleared by the FDA on July 1, 2011 through the 510(k) approval process as an intraoral device for anterior advancement of the tongue base by means of a bone screw threaded with a suture. It is indicated for the treatment of mild or moderate OSA and/or snoring. The literature, to date, has been limited by small numbers of subjects, and a literature review conducted by the manufacturer of the ENCORE System concluded that the evidence currently available has been graded as low-level evidence regarding safety and efficacy (Sezen, 2011).

Injection snoreplasty has been proposed as a treatment of both snoring and OSA. This procedure, frequently done in one to three separate treatments, involves injection of a chemical (Sotradecol) into the soft palate and uvula. Sotradecol is known as a sclerotherapy agent, and causes scarring via an inflammatory reaction in the tissues to which it is exposed. The scarring caused by Sotradecol causes the flabby loose tissue in the back of the throat to shrink and tighten, which is proposed to open the upper airway and decrease the symptoms of snoring and OSA.

The Pillar Palatal Implant System (Restore Medical, Inc. St. Paul, MN) consists of three narrow threads of braided polyester slightly less than an inch in length that are inserted under the skin of the soft palate, using a delivery tool. One is placed in the midline and one each in right and left lateral locations. The procedure can be performed in the physician’s office under local anesthesia, and over the next few weeks, scar tissue grows around the threads further stiffening the palate. The implants are designed to be permanent structures but can be removed if necessary for reasons of infection or instability. Post-operative pain is claimed to be mild and short lived with rapid resumption of normal activities and diet (unlike LAUP and RFVTR). The Pillar system received market clearance from the U.S. Food & Drug Administration in 2003. Common complications include implant extrusion, pain, sensation of a foreign body, cellulitis and difficulty swallowing (Povolotski, 2020).

HNS devices consist of three components: a pulse generator, a breathing sensor lead which monitors and senses breathing patterns, and a stimulation lead which delivers mild stimulation to the genioglossus nerve. This stimulation causes enlargement and stabilization of both the retrolingual airway and the retropalatal space and is designed to work in synchrony with respiration to allow for unobstructed inspiration. A small remote allows the individual to turn the device on each night and turn it off upon awakening. While the Inspire device is currently the only FDA approved device, a second device, THN Sleep Therapy (ImThera, San Diego, CA) is undergoing phase III clinical trials.

The Inspire Upper Airway Stimulation (UAS) is indicated for individuals aged 22 or older with moderate to severe OSA who have failed or cannot tolerate positive airway pressure treatments and who do not have complete concentric collapse at the soft palate level. Contraindications for the device are noted as:

• Central + mixed apneas > 25% of the total apnea–hypopnea index (AHI)
• Any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate
• Any condition or procedure that has compromised neurological control of the upper airway
• Patients who are unable or do not have the necessary assistance to operate the sleep remote
• Patients who are pregnant or plan to become pregnant
• Patients who will require magnetic resonance imaging (MRI)
• Patients with an implantable device that may be susceptible to unintended interaction with the Inspire system. Consult the device manufacturer to assess the possibility of interaction.

In addition to the above contraindications, the use of Inspire UAS in individuals with a BMI of greater than 32 or an RDI of greater than 65 has not been specifically studied and may be associated with a decreased likelihood of treatment response. While individuals with a BMI of 32 or greater or an RDI of 65 or greater were included in registry analysis studies, there are no published studies evaluating clinical outcomes associated with the use of HNS in this population.

Potential Risks

The level of risk associated with the various methods of OSA treatment varies dependent upon the level of invasiveness. The use of oral appliances poses little risk, but proper fitting should be done to assure optimal efficacy. The risks associated with CPAP and its derivatives are not life threatening but include disturbed sleep until the user is acclimated to the device.

Various surgical treatments for OSA all include the standard risks associated with all surgical treatments, including infection, bleeding, pain and discomfort. Not all procedures are guaranteed to be 100% successful, and results may vary. All of these surgeries result in permanent reconfiguration of the anatomical position of the upper airway, which may have unintended consequences. Persons undergoing jaw realignment should be especially aware that this surgery will most likely affect their appearance.

Apnea-Hypopnea index (AHI) or Respiratory disturbance index (RDI): A measure of apnea severity defined by the total number of episodes of apnea or hypopnea during a full period of sleep divided by the number of hours asleep. For the purposes of this document, the terms AHI and RDI are interchangeable, although they may differ slightly in clinical use.

Central sleep apnea (CSA): Sleep apnea caused by decreased respiratory center output in the brain. This sleep apnea syndrome is not as common as OSA but may be associated with similar symptoms.

Continuous positive airway pressure (CPAP): Noninvasive treatment for OSA that involves delivery of pressurized air during sleep through a device that snugly covers the nose. Considered the gold standard treatment of OSA.

Obstructive sleep apnea (OSA): A condition which is characterized by cessation of breathing during sleep, caused by temporary collapse of the upper airway.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Uvulopalatopharyngoplasty (UPPP), Soft Tissue Reconstruction, Jaw Realignment Surgery
When services may be Medically Necessary when criteria are met:

When services are Not Medically Necessary:
For the procedure and diagnosis codes listed above when criteria are not met, or when the code describes a procedure indicated in the Position Statement section as not medically necessary, or for the following diagnosis:

Hypoglossal nerve stimulation (HNS)
When services may be Medically Necessary when criteria are met:

When services are Not Medically Necessary:
For the procedure and diagnosis codes listed above when criteria are not met, or when the code describes a procedure indicated in the Position Statement section as not medically necessary, or for the following diagnosis:

Other procedures
When services are Not Medically Necessary:

When services are Investigational and Not Medically Necessary:
For the procedures listed above, for all other diagnoses, or when the code describes a procedure indicated in the Position Statement section as investigational and not medically necessary.

When services are also Investigational and Not Medically Necessary:

Peer Reviewed Publications:

1. Alkhalil M, Lockey R. Pediatric obstructive sleep apnea syndrome (OSAS) for the allergist: Update on the assessment and management. Ann Allergy Asthma Immunol. 2011; 107(2):104-109.
2. Baba RY, Mohan A, Metta VV, Mador MJ. Temperature controlled radiofrequency ablation at different sites for treatment of obstructive sleep apnea syndrome: a systematic review and meta-analysis. Sleep Breath. 2015; 19(3):891-910.
3. Back LJ, Liukko T, Rantanen I, et al. Radiofrequency surgery of the soft palate in the treatment of mild obstructive sleep apnea is not effective as a single-stage procedure: a randomized single-blinded placebo-controlled trial. Laryngoscope. 2009; 119(8):1621-1627.
4. Benninger M, Walner D. Obstructive sleep-disordered breathing in children. Clin Cornerstone. 2007; 9 Suppl 1:S6-12.
5. Bertoletti F, Indelicato A, Banfi P, Capolunghi B. Sleep apnoea/hypopnea syndrome: combination therapy with the Pillar palatal implant technique and continuous positive airway pressure (CPAP). A preliminary report. B-ENT. 2009; 5(4):251-257.
6. Boon M, Huntley C, Steffen A, et al.; ADHERE Registry Investigators. Upper airway stimulation for obstructive sleep apnea: Results from the ADHERE registry. Otolaryngol Head Neck Surg. 2018; 159(2):379-385.
7. Boroosan A, Salapatas AM, Friedman M. Clinical predictors of OSA treatment success following implantation of a hypoglossal nerve stimulation device. Otolaryngol Head Neck Surg. 2022; 167(5):891-895.
8. Bosschieter PFN, de Vries N, Mehra R, et al; ADHERE Registry Investigators. Similar effect of hypoglossal nerve stimulation for obstructive sleep apnea in 5 disease severity categories. J Clin Sleep Med. 2022; 18(6):1657-1665.
9. Boudewyns A, Van De Heyning P. Temperature-controlled radiofrequency tissue volume reduction of the soft palate (somnoplasty) in the treatment of habitual snoring: results of a European multicenter trial. Acta Otolaryngol. 2000; 120(8):981-985.
10. Brietzke SE, Mair EA. Injection snoreplasty: extended follow-up and new objective data. Otolaryngol Head Neck Surg. 2003; 128(5):605-615.
11. Browaldh N, Bring J, Friberg D. SKUP(3) RCT; continuous study: Changes in sleepiness and quality of life after modified UPPP. Laryngoscope. 2016 Jun; 126(6):1484-1491.
12. Buller M, Jodeh DS, Rottgers SA. Maxillomandibular advancement for the treatment of obstructive sleep apnea in patients with normal or class I malocclusion. J Craniofac Surg. 2020; 31(3):716-719.
13. Camacho M, Nesbitt NB, Lambert E, et al. Laser-assisted uvulopalatoplasty for obstructive sleep apnea: a systematic review and meta-analysis. Sleep. 2017; 40(3).
14. Certal VF, Zaghi S, Riaz M, et al. Hypoglossal nerve stimulation in the treatment of obstructive sleep apnea: A systematic review and meta-analysis. Laryngoscope. 2015; 125(5):1254-1264.
15. Choi JH, Kim SN, Cho JH. Efficacy of the Pillar implant in the treatment of snoring and mild-to-moderate obstructive sleep apnea: a meta-analysis. Laryngoscope. 2013; 123(1):269-276.
16. Costantino A, Rinaldi V, Moffa A, et al. Hypoglossal nerve stimulation long-term clinical outcomes: a systematic review and meta-analysis. Sleep Breath. 2020; 24(2):399-411.
17. Darrow DH. Surgery for pediatric sleep apnea. Otolaryngol Clin North Am. 2007; 40(4):855-875.
18. De Kermadec H, Blumen MB, Engalenc D, et al. Radiofrequency of the soft palate for sleep-disordered breathing: a 6-year follow-up study. Eur Ann Otorhinolaryngol Head Neck Dis. 2014; 131(1):27-31.
19. DeRowe A, Gunther E, Fibbi A, et al. Tongue-base suspension with a soft tissue-to-bone anchor for obstructive sleep apnea: preliminary clinical results of a new minimally invasive technique. Otolaryngol Head Neck Surg. 2000; 122(1):100-103.
20. Diercks GR, Wentland C, Keamy D, et al. Hypoglossal nerve stimulation in adolescents with Down syndrome and obstructive sleep apnea. JAMA Otolaryngol Head Neck Surg. 2018; 144(1):37-42.
21. Dubin MG, Senior BA. The limitations of isolated palatal surgery for patients with obstructive sleep apnea. Otolaryngol Clin North Am. 2003; 36(3):511-517.
22. Elshaug AG, Moss JR, Southcott AM, Hiller JE. Redefining success in airway surgery for obstructive sleep apnea: a meta analysis and synthesis of the evidence. Sleep. 2007; 30(4):461-467.
23. Farrar J, Ryan J, Oliver E, et al. Radiofrequency ablation for the treatment of obstructive sleep apnea: a meta-analysis. Laryngoscope. 2008; 118(10):1878-1883.
24. Ferguson KA, Heighway K, Ruby RR. A randomized trial of laser-assisted uvulopalatoplasty in the treatment of mild obstructive sleep apnea. Am J Respir Crit Care Med. 2003; 167(1):15-19.
25. Ferguson M, Smith TL, Zanation AM, Yarbrough WG. Radiofrequency tissue volume reduction: multilesion vs. single-lesion treatments of snoring. Arch Otol Laryngol, Head Neck. 2001; 127(9):1113-1118.
26. Fernandez-Julian E, Munoz N, Achiques MT, et al. Randomized study comparing two tongue base surgeries for moderate to severe obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg. 2009; 140(6):917-923.
27. Fibbi A, Ameli F, Brocchetti F, et al. Tongue base suspension and radiofrequency volume reduction: a comparison between 2 techniques for the treatment of sleep-disordered breathing. Am J Otolaryngol. 2009; 30(6):401-406.
28. Franklin KA, Anttila H, Axelsson S, et al. Effects and side-effects of surgery for snoring and obstructive sleep apnea—a systematic review. Sleep. 2009; 32(1):27-36.
29. Friberg D, Sundman J, Browaldh N. Long-term evaluation of satisfaction and side effects after modified uvulopalatopharyngoplasty. Laryngoscope. 2020; 130(1):263-268.
30. Friedman M, Ibrahim H, Lee G, et al. Combined uvulopalatopharyngoplasty and radiofrequency tongue base reduction for treatment of obstructive sleep apnea/hypopnea syndrome. Otolaryngol Head Neck Surg. 2003; 129(6):611-621.
31. Friedman M, Schalch P, Lin HC, et al. Palatal implants for the treatment of snoring and obstructive sleep apnea/hypopnea syndrome. Otolaryn Head Neck Surg. 2008; 138(2):209-216.
32. Friedman M, Vidyasagar R, Bliznikas D, Joseph N. Does severity of obstructive sleep apnea/hypopnea syndrome predict uvulopalatopharyngoplasty outcome? Laryngoscope. 2005; 115(12):2109-2113.
33. Friedman M, Vidyasagar R, Bliznikas D, Joseph NJ. Patient selection and efficacy of pillar implant technique for treatment of snoring and obstructive sleep apnea/hypopnea syndrome. Otolaryngol Head Neck Surg. 2006; 134(2):187-196.
34. Gillespie MB, Soose RJ, Woodson BT, et al.; STAR Trial Investigators. Upper airway stimulation for obstructive sleep apnea: patient-reported outcomes after 48 months of follow-up. Otolaryngol Head Neck Surg. 2017; 156(4):765-771.
35. Gillespie MB, Wylie PE, Lee-Chiong T, Rapoport DM. Effect of palatal implants on continuous positive airway pressure and compliance. Otolaryngol Head Neck Surg. 2011; 144(2):230-236.
36. Giménez S, Altuna M, Blessing E, et al. Sleep disorders in adults with Down syndrome. J Clin Med. 2021; 10(14):3012.
37. Göktas Ö, Solmaz M, Göktas G, Olze H. Long-term results in obstructive sleep apnea syndrome (OSAS) after laser-assisted uvulopalatoplasty (LAUP). PLoS One. 2014; 9(6):e100211.
38. Guilleminault C, Lee JH, Chan A. Pediatric obstructive sleep apnea syndrome. Arch Pediatr Adolesc Med. 2005; 159(8):775-785.
39. He M, Yin G, Zhan S, et al. Long-term efficacy of uvulopalatopharyngoplasty among adult patients with obstructive sleep apnea: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2019; 161(3):401-411.
40. Heiser C, Maurer JT, Hofauer B, et al. Outcomes of upper airway stimulation for obstructive sleep apnea in a multicenter German postmarket study. Otolaryngol Head Neck Surg. 2017; 156(2):378-384.
41. Heiser C, Steffen A, Boon M, et al.; ADHERE registry investigators. Post-approval upper airway stimulation predictors of treatment effectiveness in the ADHERE registry. Eur Respir J. 2019; 53(1):1801405.
42. Hoban TF, Chervin RD. Sleep-related breathing disorders of childhood: description and clinical picture, diagnosis, and treatment approaches. Sleep Med Clin. 2007; 2(3):445-462.
43. Holty JE, Guilleminault C. Maxillomandibular advancement for the treatment of obstructive sleep apnea: a systematic review and meta-analysis. Sleep Med Rev. 2010; 14(5):287-297.
44. Huntley C, Chou DW, Doghramji K, Boon M. Comparing upper airway stimulation to expansion sphincter pharyngoplasty: a single university experience. Ann Otol Rhinol Laryngol. 2018; 127(6):379-383.
45. Huntley C, Steffen A, Doghramji K, et al. Upper airway stimulation in patients with obstructive sleep apnea and an elevated body mass index: A multi-institutional review. Laryngoscope. 2018; 128(10):2425-2428.
46. Huntley C, Topf MC, Christopher V, et al. Comparing upper airway stimulation to transoral robotic base of tongue resection for treatment of obstructive sleep apnea. Laryngoscope. 2019; 129(4):1010-1013.
47. Ibrahim B, de Freitas Mendonca MI, Gombar S, et al. Association of systemic diseases with surgical treatment for obstructive sleep apnea compared with continuous positive airway pressure. JAMA Otolaryngol Head Neck Surg. 2021; 147(4):329-335.
48. Kennedy B, Lasserson TJ, Wozniak DR, Smith I. Pressure modification or humidification for improving usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2019; 12(12):CD003531.
49. Kent DT, Carden KA, Wang L, et al. Evaluation of hypoglossal nerve stimulation treatment in obstructive sleep apnea. JAMA Otolaryngol Head Neck Surg. 2019; 145(11):1044-1052.
50. Khot SP, Barnett HM, Davis AP, et al. Novel and modifiable factors associated with adherence to continuous positive airway pressure therapy initiated during stroke rehabilitation: An exploratory analysis of a prospective cohort study. Sleep Med. 2022; 97:43-46.
51. Kompelli AR, Ni JS, Nguyen SA, et al. The outcomes of hypoglossal nerve stimulation in the management of OSA: A systematic review and meta-analysis. World J Otorhinolaryngol Head Neck Surg. 2018; 5(1):41-48.
52. Kuhnel T; Schurr C; Wagner B, Geisler P. Morphological changes of the posterior airway space after tongue base suspension. Laryngoscope. 2005; 115(3):475-480.
53. Kushida CA, Littner MR, Hirshkowitz M, et al; American Academy of Sleep Medicine. Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep. 2006; 29(3):375-380.
54. Li C, Boon M, Ishman SL, Suurna MV. Hypoglossal nerve stimulation in three adults with Down syndrome and severe obstructive sleep apnea. Laryngoscope. 2019; 129(11):E402-E406.
55. Li KK, Powell NB, Riley RW, et al. Temperature-controlled radiofrequency tongue base reduction for sleep-disordered breathing; long term outcomes. Otolaryngol Head Neck Surg. 2002; 127(3):230-234.
56. Li KK. Surgical management of obstructive sleep apnea. Clin Chest Med. 2003: 24(2):365-370.
57. Lin CM, Davidson TM, Ancoli-Israel S. Gender differences in obstructive sleep apnea and treatment implications. Sleep Med Rev. 2008; 12(6):481-496.
58. Llewellyn CM, Noller MW, Camacho M. Cautery-assisted palatal stiffening operation for obstructive sleep apnea: A systematic review and meta-analysis. World J Otorhinolaryngol Head Neck Surg. 2018; 5(1):49-56.
59. Mair, EA, Day RH. Cautery-assisted palatal stiffening operation. Otolaryngol Head Neck Surg. 2000; 122(4):547-556.
60. Marcus CL, Rosen G, Ward SL, et al. Adherence to and effectiveness of positive airway pressure therapy in children with obstructive sleep apnea. Pediatrics. 2006; 117(3):e442-451.
61. Marklund M, Stenlund H, Franklin KA. Mandibular advancement devices in 630 men and women with obstructive sleep apnea and snoring: tolerability and predictors of treatment success. Chest. 2004; 125(4):1270-1278.
62. Maurer JT, Verse T, Stuck BA, et al. Palatal implants for primary snoring: short-term results of a new minimally invasive surgical technique. Otolaryngol Head Neck Surg. 2005; 132(1):125-131.
63. Mehta A, Qian J, Petocz P, et al. A randomized controlled study of a mandibular advancement splint for obstructive sleep apnea. Am J Respir Crit Care Med. 2001; 163(6):1457-1461.
64. Miller FR, Watson D, Malis D. Role of the tongue base suspension suture with the Repose System bone screw in the multilevel surgical management of obstructive sleep apnea. Otolaryngol Head Neck Surg. 2002; 126(4):392-398.
65. Millman RP, Carlisle CC, Rosenberg C, et al. Simple predictors of uvulopalatopharyngoplasty outcome in the treatment of obstructive sleep apnea. Chest. 2000; 118(4):1025-1030.
66. Mulholland GB, Jeffery CC, Ziai H, et al. Multilevel palate and tongue base surgical treatment of obstructive sleep apnea: a systematic review and meta-analysis. Laryngoscope. 2019; 129(7):1712-1721.
67. Naik S, Al-Halawani M, Kreinin I, Kryger M. Centers for Medicare and Medicaid Services positive airway pressure adherence criteria may limit treatment to many Medicare beneficiaries. J Clin Sleep Med. 2019; 15(2):245-251.
68. Nelson LM. Combined temperature-controlled radiofrequency tongue reduction and UPPP in apnea surgery. Ear Nose Throat J. 2001; 80(9):640-644.
69. Neruntarat C. Uvulopalatal flap for obstructive sleep apnea: short-term and long-term results. Laryngoscope. 2011; 121(3):683-687.
70. Nordgård S, Hein G, Stene BK, et al. One-year results: palatal implants for the treatment of obstructive sleep apnea. Otolaryngol Head Neck Surg. 2007; 136(5):818-822.
71. Omur M, Ozturan D, Elez F, et al. Tongue base suspension combined with UPPP in severe OSA patients. Otolaryngol Head Neck Surg. 2005; 133(2):218-223.
72. Pang KP, Terris DJ. Modified cautery-assisted palatal stiffening operation: new method for treating snoring and mild obstructive sleep apnea. Otolaryngol Head Neck Surg. 2007; 136(5):823-826.
73. Petrov ME, Lichstein KL. Differences in sleep between black and white adults: an update and future directions. Sleep Med. 2016; 18:74-81.
74. Povolotskiy R, Abraham ME, Leverant AB, et al. Complications of palatal pillar implants: an analysis of the MAUDE database and literature review. Am J Otolaryngol. 2020; 41(1):102303.
75. Qureshi A, Ballard RD. Obstructive sleep apnea. J Allergy Clin Immunol. 2003; 112(4):643-651.
76. Romano M, Karanxha L, Baj A, et al. Maxillomandibular advancement for the treatment of obstructive sleep apnoea syndrome: a long-term follow-up. Br J Oral Maxillofac Surg. 2020; 58(3):319-323.
77. Sangal RB, Sudan N. Baseline lighter sleep and lower saturation are associated with improved sleepiness and adherence on continuous rather than autotitrating positive airway pressure. Clin EEG Neurosci. 2020; 51(3):174-179.
78. Server EA, Alkan Z, Yiğit Ö, Yasak AG. Long-term results of pillar implant procedure. Kulak Burun Bogaz Ihtis Derg. 2016; 26(5):258-64.
79. Sezen OS, Aydin E, Eraslan G, et al. Modified tongue base suspension for multilevel or single level obstructions in sleep apnea: Clinical and radiologic results. Auris Nasus Larynx. 2011; 38:487-494.
80. Shah J, Russell JO, Waters T, et al. Uvulopalatopharyngoplasty vs CN XII stimulation for treatment of obstructive sleep apnea: a single institution experience. Am J Otolaryngol. 2018; 39(3):266-270.
81. Sher AE, Flexon PB, Hillman D, et al. Temperature-controlled radiofrequency tissue volume reduction in the human soft palate. Otolaryngol Head Neck Surg. 2001; 125(4):312-318.
82. Sher AE. Upper airway surgery for obstructive sleep apnea. Sleep Med Rev. 2002; 6(3):195-212.
83. Silverberg D, Iaina A. Treating obstructive sleep apnea improves essential hypertension and quality of life. Am Fam Phys. 2002; 65(2):229-236.
84. Song SA, Wei JM, Buttram J, et al. Hyoid surgery alone for obstructive sleep apnea: A systematic review and meta-analysis. Laryngoscope. 2016; 126(7):1702-1708.
85. Soose RJ, Gillespie MB. Upper airway stimulation therapy: a novel approach to managing obstructive sleep apnea. Laryngoscope. 2016; 126 Suppl 7:S5-S8.
86. Soose RJ, Woodson BT, Gillespie MB, et al.; STAR Trial Investigators. Upper airway stimulation for obstructive sleep apnea: self-reported outcomes at 24 Months. J Clin Sleep Med. 2016; 12(1):43-48.
87. Steffen A, Sommer JU, Hofauer B, et al. Outcome after one year of upper airway stimulation for obstructive sleep apnea in a multicenter German post-market study. Laryngoscope. 2018; 128(2):509-515.
88. Stenerson ME, Yu PK, Kinane TB, et al. Long-term stability of hypoglossal nerve stimulation for the treatment of obstructive sleep apnea in children with Down syndrome. Int J Pediatr Otorhinolaryngol. 2021; 149:110868.
89. Steward DL. Effectiveness of multilevel (tongue and palate) radiofrequency tissue ablation for patients with obstructive sleep apnea syndrome. Laryngoscope. 2004a; 114(12):2073-2084.
90. Steward DL, Huntley TC, Woodson BT, et al. Palate implants for obstructive sleep apnea: multi-institution, randomized, placebo-controlled study. Otolaryngol Head Neck Surg. 2008; 139(4):506-510.
91. Steward DL, Weaver EM, Woodson BT. A comparison of radiofrequency treatment schemes for obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg. 2004b; 130(5):579-585.
92. Strollo PJ. Indications for treatment of obstructive sleep apnea in adults. Clin Chest Med. 2003; 24(2):307-313.
93. Strollo PJ, Gillespie MB, Soose RJ, et al.; Stimulation Therapy for Apnea Reduction (STAR) Trial Group. Upper airway stimulation for obstructive sleep apnea: durability of the treatment effect at 18 months. Sleep. 2015; 38(10):1593-1598.
94. Strollo PJ, Soose RJ, Maurer JT, et al. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med. 2014; 370(2):139-149.
95. Stuck BA, Maurer JT, Hormann K. Tongue base reduction with radiofrequency tissue ablation: preliminary results after two treatment sessions. Sleep Breath. 2000; 4(4):155-162.
96. Stuck BA, Maurer JT, Verse T, Hormann K. Tongue base reduction with temperature-controlled radiofrequency volumetric tissue reduction for treatment of obstructive sleep apnea syndrome. Acta Otolaryngol. 2002; 122(5):531-536.
97. Sundman J, Browaldh N, Fehrm J, Friberg D. Eight-year follow-up of modified uvulopalatopharyngoplasty in patients with obstructive sleep apnea. Laryngoscope. 2021; 131(1):E307-E313.
98. Suurna MV, Steffen A, Boon M, et al; ADHERE Registry Investigators. Impact of Body Mass Index and Discomfort on Upper Airway Stimulation: ADHERE Registry 2020 Update. Laryngoscope. 2021; 131(11):2616-2624.
99. Terris DJ, Kunda LD, Gonella MC. Minimally invasive tongue base surgery for obstructive sleep apnea. J Laryngol Otol. 2002; 116(9):716-721.
100. Terris DJ, Coker JF, Thomas A J, Chavoya M. Preliminary findings from a prospective, randomized trial of two palatal operations for sleep-disordered breathing. Otolaryngol Head Neck Surg. 2002; 127(4):315-323.
101. Thaler E, Schwab R, Maurer J, et al. Results of the ADHERE upper airway stimulation registry and predictors of therapy efficacy. Laryngoscope. 2020; 130(5):1333-1338.
102. Thomas AJ, Chavoya M, Terris DJ. Preliminary findings from a prospective, randomized trial of two tongue-base surgeries for sleep-disordered breathing. Otolaryngol Head Neck Surg. 2003; 129(5):539-546.
103. Troell RJ. Radiofrequency techniques in the treatment of sleep-disordered breathing. Otolaryngol Clin North Am. 2003; 36(3):473-493.
104. van den Broek E, Richard W, van Tinteren H, et al. UPPP combined with radiofrequency thermotherapy of the tongue base for the treatment of obstructive sleep apnea syndrome. Eur Arch Otorhinolaryngol. 2008; 265(11):1361-1365.
105. Van Tassel J, Chio E, Silverman D, et al. Hyoid suspension with UPPP for the treatment of obstructive sleep apnea. Ear Nose Throat J. 2023; 102(5):NP212-NP219.
106. Vicini C, Dallan I, Campanini A, et al. Surgery vs. ventilation in adult severe obstructive sleep apnea syndrome. Am J Otolaryngol. 2010; 31(1):14-20.
107. Volner K, Dunn B, Chang ET, et al. Transpalatal advancement pharyngoplasty for obstructive sleep apnea: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2017; 274(3):1197-1203.
108. Walia HK, Thompson NR, Strohl KP, et al. Upper airway stimulation vs positive airway pressure impact on BP and sleepiness symptoms in OSA. Chest. 2020; 157(1):173-183.
109. Walker RP, Levine HL, Hopp ML, Greene D. Extended follow-up of palatal implants for OSA treatment. Otolaryngol Head Neck Surg. 2007; 137(5):822-827.
110. Wassmuth Z, Mair E, Loube D, Leonard D. Cautery-assisted palatal stiffening operation for the treatment of obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg. 2000; 123(1 Pt 1):55-60.
111. Watanabe T, Kumano-Go T, Suganuma N, et al. The relationship between esophageal pressure and apnea hypopnea index in obstructive sleep apnea-hypopnea syndrome. Sleep Res Online. 2000; 3(4):169-172.
112. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc. 2008; 5(2):173-178.
113. Withrow K, Evans S, Harwick J, et al. Upper airway stimulation response in older adults with moderate to severe obstructive sleep apnea. Otolaryngol Head Neck Surg. 2019; 161(4):714-719.
114. Woodson BT. Transpalatal advancement pharyngoplasty. Oper Tech Otolaryn. 2007; 18(1):11-16.
115. Woodson BT, Derowe A, Hawke M, et al. Pharyngeal suspension suture with repose bone screw for obstructive sleep apnea. Otolaryngol Head Neck Surg. 2000; 122(3):395-401.
116. Woodson BT, Gillespie MB, Soose RJ, et al.; STAR Trial Investigators; STAR Trial Investigators. Randomized controlled withdrawal study of upper airway stimulation on OSA: short- and long-term effect. Otolaryngol Head Neck Surg. 2014; 151(5):880-887.
117. Woodson BT, Nelson L, Mickelson S, et al. A multi-institutional study of radiofrequency volumetric tissue reduction for OSAS. Otolaryngol Head Neck Surg. 2001; 125(4):303-311.
118. Woodson BT, Robinson S, Lim HJ. Transpalatal advancement pharyngoplasty outcomes compared with uvulopalatopharyngoplasty. Otolaryngol Head Neck Surg. 2005; 133(2):211-217.
119. Woodson BT, Soose RJ, Gillespie MB, et al.; STAR Trial Investigators. Three-year outcomes of cranial nerve stimulation for obstructive sleep apnea: the STAR trial. Otolaryngol Head Neck Surg. 2016; 154(1):181-188.
120. Woodson BT, Steward DL, Mickelson S, et al. Multicenter study of a novel adjustable tongue-advancement device for obstructive sleep apnea. Otolaryngol Head Neck Surg. 2010; 143(4):585-590.
121. Woodson BT, Steward DL, Weaver EM, Javaheri S. A randomized trial of temperature-controlled radiofrequency, continuous positive airway pressure, and placebo for obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg. 2003; 128(6):848-861.
122. Woodson BT, Strohl KP, Soose RJ, et al. Upper airway stimulation for obstructive sleep apnea: 5-year outcomes. Otolaryngol Head Neck Surg. 2018; 159(1):194-202.
123. Wozniak DR, Lasserson TJ, Smith I. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2014; (1):CD007736.
124. Yang MC, Hsu YB, Lan MY, Lan MC. The comparison of multilevel surgery (hyoid myotomy and suspension with uvulopalatopharyngoplasty) with CPAP in moderate to severe OSAS patients. Eur Arch Otorhinolaryngol. 2020; m277(8):2349-2355.
125. Yu JL, Mahmoud A, Thaler ER. Transoral robotic surgery versus upper airway stimulation in select obstructive sleep apnea patients. Laryngoscope. 2019; 129(1):256-258.
126. Yu PK, Stenerson M, Ishman SL, et al. Evaluation of upper airway stimulation for adolescents with Down syndrome and obstructive sleep apnea. JAMA Otolaryngol Head Neck Surg. 2022; 148(6):522-528.
127. Zaghi S, Holty JE, Certal V, et al. Maxillomandibular advancement for treatment of obstructive sleep apnea: A meta-analysis. JAMA Otolaryngol Head Neck Surg. 2016; 142(1):58-66.

Government Agency, Medical Society, and Other Authoritative Publications:

1. American Academy of Otolaryngology Head and Neck Surgery (AAO-HNS). Position Statements: Available at: http://www.entnet.org/content/position-statements. Accessed on June 10, 2024.
   • Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea (OSA). April 22, 2021.
   • Midline Glossectomy for OSA. Revised April 22, 2021.
   • Submucosal Ablation of the Tongue Base for OSAS. April 22, 2021.
   • Surgical Management of Obstructive Sleep Apnea. April 22, 2021.
   • Tongue Based Procedures. November 24, 2021.
   • Tongue Suspension. April 21, 2021.
   • Treatment of Obstructive Sleep Apnea. Revised April 22, 2021.
   • Uvulopalatopharyngoplasty. Revised April 22, 2021.
2. American Association of Oral and Maxillofacial Surgeons (AAOMS). Criteria for Orthognathic Surgery. 2020. Available at: https://www.aaoms.org/docs/practice_resources/clinical_resources/ortho_criteria.pdf. Accessed on June 10, 2024.
3. American College of Physicians (ACP). Management of Obstructive Sleep Apnea in Adults. October 1, 2013. Available at: https://annals.org/aim/fullarticle/1742606/management-obstructive-sleep-apnea-adults-clinical-practice-guideline-from-american. Accessed on June 10, 2024.
4. Aurora RN, Casey KR, Kristo D, et al. American Academy of Sleep Medicine. Practice parameters for the surgical modifications of the upper airway for obstructive sleep apnea in adults. Sleep. 2010; 33(10):1408-1413. Available at: http://www.aasmnet.org/Resources/PracticeParameters/PP_SurgicalModificationsOSA.pdf. Accessed on June 10, 2024.
5. Caples SM, Rowley JA, Prinsell JR, et al. Surgical modifications of the upper airway for obstructive sleep apnea in adults: a systematic review and meta-analysis. Sleep. 2010; 33(10):1396-1407.
6. Centers for Medicare & Medicaid Services (CMS). National Coverage Analysis, Decision Memo. Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea. CAG-00093N. October 30, 2001. Available at: https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=19&fromdb=true. Accessed on June 10, 2024.
7. Chang JL, Goldberg AN, Alt JA, et al. International consensus statement on obstructive sleep Apnea. Int Forum Allergy Rhinol. 2023; 13(7):1061-1482.
8. Epstein LJ, Kristo D, Strollo PJ, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009; 5(3):263-276. Available at: http://www.aasmnet.org/Resources/ClinicalGuidelines/OSA_Adults.pdf. Accessed on June 10, 2024.
9. Giralt-Hernando M, Valls-Ontañón A, Guijarro-Martínez R, et al. Impact of surgical maxillomandibular advancement upon pharyngeal airway volume and the apnoea-hypopnoea index in the treatment of obstructive sleep apnoea: systematic review and meta-analysis. BMJ Open Respir Res. 2019; 6(1):e000402.
10. Marcus CL, Brooks LJ, Draper KA, et al; American Academy of Pediatrics. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012; 130(3):e714-755.
11. Qaseem A, Holty JC, Owens DK, et al. American College of Physicians (ACP). Management of obstructive sleep apnea in adults: a Clinical Practice Guideline from the American College of Physicians. Ann Intern Med. 2013; 159(7):471-483. Available at: http://annals.org/article.aspx?articleid=1742606. Assessed on June 10, 2024.
12. Randerath WJ, Verbraecken J, Andreas S, et al. European Respiratory Society task force on non-CPAP therapies in sleep apnea. Non-CPAP therapies in obstructive sleep apnea. Eur Respir J. 2011; 37(5):1000-1028.
13. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol. 2008; 52(8):686-717.
14. Sundaram S, Bridgman SA, Lim J, Lasserson TJ. Surgery for obstructive sleep apnoea. Cochrane Database Syst Rev. 2005;(4):CD001004.
15. U.S. Food and Drug Administration (FDA) Center for Devices and Radiologic Health (CDRH) 510 (k) Premarket Notification Database. Accessed on June 10, 2024.
    • Encore™ Bone Screw System. Summary of Safety and Effectiveness. No.K183310. Rockville, MD: FDA. May 9, 2019. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K183310.
    • ENCORE^™ Tongue Suspension System. Summary of Safety and Effectiveness. No. K111179. Rockville, MD: FDA. July 1, 2011. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf11/K111179.pdf.
    • Pillar^™ Palatal Implant System. Summary of Safety and Effectiveness. No. K040417. Rockville, MD: FDA. July 28, 2004. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf4/K040417.pdf.
16. U.S. FDA. Pre-Market Approval (PMA). Rockville, MD: FDA.
    • Inspire Upper Airway Stimulation. No. P130008. April 30, 2014. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130008. Accessed on July 30, 2024.
    • Inspire Upper Airway Stimulation. No. P130008/S090. June 8, 2023. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130008S090A.pdf. Accessed on July 30, 2024.

1. Snoring, Sleeping Disorders, and Sleep Apnea. American Academy of Otolaryngology - Head and Neck Surgery. Available at: https://www.enthealth.org/conditions/snoring-sleeping-disorders-and-sleep-apnea/. Accessed on June 10, 2024.
2. Sleep Apnea. National Heart, Lung, and Blood Institute. Available at: https://www.nhlbi.nih.gov/health-topics/sleep-apnea. Accessed on June 10, 2024.
3. National Council on Aging (NCOA). Sleep Apnea Statistics and Facts You Should Know. May 8, 2024. Available at: August 8, 2024. Accessed on August 8, 2024.

AIRLIFT^™ 
AIRvance System
Apnea/Hypopnea Index (AHI)
Cautery-Assisted Palatal Stiffening Operation (CAPSO)
Coblation
ENCORE Tongue Suspension System
Genioglossal (Genioglossus) Advancement
Inspire Upper Airway Stimulation system
Laser-Assisted Uvulopalatopharyngoplasty (LAUP)
Obstructive Sleep Apnea
Palatal Implants
Pillar Implant
Radiofrequency Ablation of Palatal Tissues and the Base of Tongue
Radiofrequency Volumetric Tissue Reduction (RFVTR) of the soft palate and/or the base of the tongue
RF Thermal Ablation
Somnoplasty System
Transpalatal advancement pharyngoplasty
Uvulopalatopharyngoplasty

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association